CRISPR/Cas9 Genome Editing
CRISPR
CRISPR
Homologous Recombination
CRISPR and crRNAs
Overview of DNA Repair
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jul 16, 2026

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells
Published on: August 25, 2017
Samuel N Effah1,2, Shirley C Barrera1,2, Nahia Urturi Ortiz1,2
1Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
CRISPR/Cas9 gene editing, now FDA-approved for sickle cell anemia, shows promise for chronic diseases like HIV-1. Success depends on delivery, editing efficiency, and repair outcomes, with new analytical tools aiding prediction.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: